Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

April 17, 2023

Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting

April 17, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 10, 2023

Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023

April 4, 2023

Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting

March 15, 2023

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

March 9, 2023

Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023

March 2, 2023

Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference

February 27, 2023

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2023

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

February 14, 2023

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

© 2023 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Cookie Policy
Contact

socials

Top